IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

Phase II clinical trials revealed that the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath-1H) is highly effective in the treatment of early relapsing-remitting multiple sclerosis. However, 30% of patients develop autoimmunity months to years after pulsed exposure to alemtuzu...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jones, Joanne L., Phuah, Chia-Ling, Cox, Amanda L., Thompson, Sara A., Ban, Maria, Shawcross, Jacqueline, Walton, Amie, Sawcer, Stephen J., Compston, Alastair, Coles, Alasdair J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2009
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2701868/
https://ncbi.nlm.nih.gov/pubmed/19546505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI37878
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky